Resection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland

Similar documents
Breast Surgery: Yesterday, Today and Tomorrow

SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Breast Cancer. Saima Saeed MD

Breast Cancer. Dr. Andres Wiernik 2017

Ductal Carcinoma in Situ (DCIS)

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.

Radiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging

A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer

What are Adequate Margins of Resection for Breast-Conserving Therapy?

Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction

Handout for Dr Allison s Lectures on Grossing Breast Specimens:

Image guided core biopsies:

What is an Adequate Lumpectomy Margin in 2018?

Pathology Report Patient Companion Guide

Page 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

New Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School

BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO

Clinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair

Evolution of Breast Surgery

Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Table of contents. Page 2 of 40

BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights

Breast Cancer Diagnosis, Treatment and Follow-up

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School

Case study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research

Oncoplastic breast surgery in a Danish perspective II: Reconstructive strategy in oncoplastic breast surgery

BREAST CANCER SURGERY. Dr. John H. Donohue

When do you need PET/CT or MRI in early breast cancer?

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction

Treatment options for the precancerous Atypical Breast lesions. Prof. YOUNG-JIN SUH The Catholic University of Korea

Breast Cancer? Breast cancer is the most common. What s New in. Janet s Case

Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node

Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

ACRIN 6666 Therapeutic Surgery Form

Conservative Surgery and Radiation Stage I and II Breast Cancer

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Consensus Guideline on Accelerated Partial Breast Irradiation

Ahmad Elahi*, Gholamreza Toogeh,Habibollah Mahmoodzadeh, Behnaz Jahanbin, Farhad Shahi,

Intraoperative. Radiotherapy

Classification System

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Principles of breast radiation therapy

Ductal carcinoma in situ (DCIS)

Ductal Carcinoma-in-Situ: New Concepts and Controversies

Breast Cancer FAQ. How does Breast Cancer spread? Breast cancer spreads by invading into

Contemporary Classification of Breast Cancer

A712(19)- Test slide, Breast cancer tissues with corresponding normal tissues

Use of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

Ines Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM

RADIOTHERAPY IN BREAST CANCER :

Types of Breast Cancer

National Mastectomy & Breast Reconstruction Audit Datasheet - Mastectomy +/- Immediate Reconstruction

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Citation Hong Kong Practitioner, 1996, v. 18 n. 2, p

COPE Library Sample

PRACTICE GUIDELINE FOR BREAST CONSERVATION THERAPY IN THE MANAGEMENT OF INVASIVE BREAST CARCINOMA

Excerpts from the American College of Surgeons Educational Courses about Breast Disease:

Current Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery

Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Breast Health. Program Objectives. Facts About Breast Cancer in the United States

Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital

Management of Ductal Carcinoma in Situ of the Breast: A Clinical Practice Guideline

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options

Understanding Your Pathology Report

Evaluation of Breast Specimens Removed by Needle Localization Technique

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection

BreastScreen Victoria Annual Statistical Report

Surgery for Breast Cancer

Clinical Investigation: Breast Cancer

Advances in Localized Breast Cancer

National Diagnostic Imaging Symposium 2013 SAM - Breast MRI 1

Objectives Intraoperative Radiation Therapy for Early Stage Breast Cancer

Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy

Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery

DCIS: Margins and the USC/VNPI

The best treatment Your guide to breast cancer treatment in England and Wales

Mauricio Camus Appuhn Associate Professor Chief, Department of Surgical Oncology, Pontificia Universidad Católica de Chile

BreastScreen Aotearoa Annual Report 2015

Quality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care

The Case FOR Oncoplastic Surgery in Small Breasts. Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

It is a malignancy originating from breast tissue

Transcription:

Resection Margins in Breast Conserving Surgery Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland

Breast Conserving Surgery 1 Probably one of the most important innovation in cancer surgery Main incentive to early diagnosis Perceived by women and doctors as first light at the end of the breast cancer tunnel Described nearly at the same time in Europe (Veronesi) and in the US (Fisher) with two options: a wider excision (quadrantectomy) vs simple removal of the tumour (tumourectomy or lumpectomy)

Breast Conserving Surgery 2 Veronesi s quadrantectomy had since the beginning less local recurrences, but also worse cosmetic results. Fisher s lumpectomy was based on the concept that breast cancer is a systemic disease and that the lump is only the tip of the iceberg. Cosmetic results more important than local recurrence rate, since the real treatment is the systemic one Local recurrence has a relevant impact on survival.

Breast Conserving Surgery 3 Now the scenario is quite different: Little impact of the TNM classification Major impact of the biology of the tumour Awareness of the great number of possible different profiles Gene profiling Oncoplastic surgery Patients needs and choices.

Local Recurrence after BCS Tumour characteristics Margin status Tumour/breast size Multifocality/centricity Type, EIC, PVI, residual microcalcifications Biological features (HR & HER2 status) Patient s characteristics: age, familial risk

0,5 CM TUBULAR G1 SENTINEL NODE NEG NO VASCULAR INVASION ER/PGR: 100% KI67: 5% HER 2 NEG 3,5 CM LOBULAR G3 7/20 METASTATIC LYMPH NODES VASCULAR INVASION ER/PGR:0 KI67: 60% HER 2 +++

Does age per se correlate with positive margins? Larger tumours in younger patients Biologically bad tumours in younger patients Less optimal margin resection in younger patients (cosmetic reasons) More skin & nipple sparing surgery in younger patients When adequate margins are obtained, no difference in local recurrence according to age

Tumour P R E P O S T

Are margins important? Independent predictors of local recurrence following conservative surgery Negative margins do not exclude residual tumor after excision Positive margins dictate re-excision or radiotherapy What about close margins?

Honestly, we do not know. But we need some consensus To avoid mastectomies that may not be necessary To spare multiple re-excisions To avoid performance of unnecessarily wide resections To reassure patients and treating physicians on the adequacy of the local treatment

When are they free? Not at ink >2 mm from ink >5 mm from ink POS FREE POS CLOSE FREE

(1) The peritumoral spread of cancer cells is often discontinuous Surgical line

(2) The biopsies on the margins of the specimen are at random. RANDOM SAMPLES

Honestly we do not know but.. <1mm positive close

To margin or not to margin? Modified by Beppe Viale from W. Shakespeare

Local-Regional Treatment of Primary Breast Cancer: Consensus Recommendations from an International Expert Panel studies show higher rates of IBTR with positive margins, but we lack consistent evidence that margins wider than tumor not touching ink decrease IBTR In general, invasive or intraductal cancer at an inked surface necessitates a re-excision. The Panel endorses the adoption of tumor not touching ink as the standard definition of an adequate negative margin in patients with invasive cancer

Local-Regional Treatment of Primary Breast Cancer: Consensus Recommendations from an International Expert Panel Since DCIS, particularly low and intermediate grade lesions, may grow discontinuously within the ducts, adequate negative margins for DCIS should be larger than those for invasive carcinoma A 2 mm margin was endorsed by the Panel as an appropriate standard. Margins less than 2 mm are not an absolute indication for mastectomy, but should be considered along with other factors influencing local recurrence rates.

Local-Regional Treatment of Primary Breast Cancer: Consensus Recommendations from an International Expert Panel Anterior and posterior margins of less than 2 mm are not of concern if there is no residual breast tissue. All suspicious micro-calcifications associated with the DCIS should be removed surgically Lobular carcinoma in situ at the margin is not considered an indication for further surgery

Still, a free margin does not eliminate the risk of local rec Tumour type Ductal vs lobular Tumour focality Extensive intraductal component High-grade vs low-grade Peritumoral vascular invasion Biological features

Tumor Biology and Local Recurrence Subtype % 5-year LR 95% CI ER/PR Pos, HER2 Neg 0.8 0.3-2.2 ER/PR Pos, HER2 Pos 1.5 0.2-10 ER/PR Neg, HER2 Pos* 8.4 2.2-30 ER/PR Neg, HER2 Neg 7.1 3.0-16.0 Nguyen PL. JCO 2008;26;2373. *no adjuvant trastuzumab

Sites of First Events Patients Trial B-31 Trial N9831 Control Group Trastuz Group Control Group number of patients Trastuz Group All patients with follow-up 872 864 807 808 Patients alive and event-free 701 781 717 758 Patients with any first event 171 83 90 50 Local or regional recurrence 35 15 22 12 Distant recurrence 111 60 63 30 Contralateral breast cancer 6 2 0 1 Other second primary cancer 15 2 3 3 Death with NED 4 4 2 4 Romand, NEJM 2005; 353:1673.

Take home messages Margins should be considered in the context of multiple factors that influence local control Obsessing about differences of 1-2mm does not take into account the uncertainties in the pathologic processing and the differences in tumour biology Margins management has biological, prognostic, cosmetic and financial implications.

The end fine Note the inked margin